ZESTY-SYSTEMS-INC.
Zesty Systems Inc., the leading company of IoT technology, announced to release Pinout, a smart, versatile gadget to control your DSLR by smartphone, to the global market.
PV
https://www.youtube.com/watch?v=R4fpITI9yuI
Purchase Pinout (Available at www.amazon.com
and Paypal from September 3rd, 2016)
https://www.letspinout.com/?#buy
Compatible to iOS and android smartphone, multi-camera control function
is added.
Comparing to the previous version ZGR-2, Pinout uses
Bluetooth LE technology and offers many convenient and advanced uses. It
supports GPS, timer control, multi-camera control, time-lapse, HDR, bulb
ramping, sensor-based functions and more.
iOS device compatibility: iOS 9.0 or above. iPhone 4S/5/5s/6/6s, apple
watch
Android device compatibility: Bluetooth Low Energy (Bluetooth
4.0 or above), android OS 4.4, 5.0, 6.0 or above.
Basic kit, Pro kit and Full kit support different functions.
Based
on the different functions, Basic kit, Pro kit and Full kit are
provided. Type A and type B are provided according to the shape
difference of the camera accessory terminal.
Loss prevention
function is included in all kits. When Pinout drops off from the camera
or far away from the smartphone, you will get an alert.
Basic kit
Basic kit supports loss/theft prevention, simple release, long exposure,
timed-release.
Retail price: $34.99
Pro kit
Pro kit supports functions included in Basic kit, and time-lapse,
distance lapse, star trail, geo tagging, geo logging.
Retail price:
$78.99
Full kit
Full kit supports functions included in Pro kit, and bulb ramping, LE
HDR, LE HDR Time-lapse, multi-camera control and sensor release.
Retail
price:$128.99
Type A
Compatibility: Nikon D5, D500, D4, D4s, D3, D3S, D3X, D2X, D2XS, D2HS, D2H, D800, D800E, D810, D810A, D700, D300, D300S, D200, Fujifilm S5 Pro
Type B
Compatibility: Nikon Df, D750, D610, D600, D90, D7200, D7100, D7000, D5500, D5300, D5200, D5100, D5000, D3300, D3200, D3100, COOLPIX A, COOLPIX P7800, COOLPIX 7700
Zesty Systems Inc.
https://www.zesty.co.jp/en/index.html
If
you want to be a Pinout distributor, please contact us sales@zesty.co.jp
View source version on businesswire.com: http://www.businesswire.com/news/home/20160906005603/en/
Contact:
Zesty Systems Inc.
Isamu Aoyama / Rie Asaka, +81-3-6666-9816
sales@zesty.co.jp
FAX:
+81-3-6666-9812
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom